Global X China Biotech UCITS ETF (CBIO)
LSE 
Summary
CBIO Chart
Crescent Biopharma: Chasing The Summit Hype
Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody, aiming for first-in-human trials in late 2025. The company is well-funded, with over $150 million in cash and a manageable burn rate, supporting operations for 2–3 years. Risks include being behind competitors and the unproven clinical potential of their lead candidate, but sector hype remains strong.
Global X China Biotech UCITS ETF (CBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Global X China Biotech UCITS ETF ever had a stock split?
Global X China Biotech UCITS ETF Profile
| LSE Exchange | US Country |
Overview
Crescent Biopharma, Inc. is a forward-looking biotechnology firm with a sharp focus on pioneering the development of innovative precision-engineered molecules. These advanced molecules are specifically designed to target validated biological pathways, offering new avenues for the treatment of patients suffering from solid tumors. Since its incorporation in 2024, Crescent Biopharma has been steadfast in its commitment to leverage cutting-edge science and technology to fill significant gaps in cancer care. Positioned at the forefront of biotechnological research and headquartered in the USA, the company strives to transform the therapeutic landscape for solid tumors, aiming to enhance the effectiveness of treatments and ultimately improve patient outcomes.
Products and Services
Crescent Biopharma, Inc. brings forth a unique portfolio of precision-engineered molecules and services, specifically designed to advance the field of oncology. Each product and service reflects the company's dedication to innovation, precision, and care.
- Precision-Engineered Molecules for Solid Tumors:
- Targeted Therapy Development:
At the heart of Crescent Biopharma’s offerings are its precision-engineered molecules that target validated biological pathways in solid tumors. These bespoke molecules are developed through rigorous research and cutting-edge technology, with a focus on improving treatment outcomes and minimizing side effects. Their innovative approach ensures that therapies are not only efficacious but also safer and more tolerable for patients, heralding a new era in oncological care.
Beyond individual molecules, Crescent Biopharma is dedicated to the development of targeted therapies that address the specific genetic and phenotypic characteristics of solid tumors. This personalized approach to treatment underscores the company's commitment to precision medicine, aiming to match each patient with the most effective therapy based on their unique tumor profile. Through targeted therapy development, Crescent Biopharma seeks to optimize cancer care, ensuring treatments are as effective and efficient as possible.
Contact Information
